-
A direct link between SARS-CoV-2 and bone loss Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-02-10 Sarah Onuora
Research demonstrates that the SARS-CoV-2 protein ORF8 drives osteoclastogenesis, establishing a direct link between viral infection and bone loss.
-
Antigen-driven T cell responses in rheumatic diseases: insights from T cell receptor repertoire studies Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-02-07 Jose Garrido-Mesa, Matthew A. Brown
-
Genome-wide mutagenesis reported in systemic sclerosis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-02-06 Carol M. Artlett, John Varga
-
Occupational dust and chemical exposures and the development of autoimmune rheumatic diseases Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-02-05 Mandana Nikpour, Kathleen Morrisroe, Alicia Calderone, Deborah Yates, Alan Silman
-
T cells in Sjögren disease Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-01-31 Holly Webster
A mouse model that reflects Sjögren disease in humans provides insights into the role of regulatory T cells and type 1 helper T cells in disease pathogenesis.
-
Virome associations in autoimmunity and COVID-19 Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-01-28 Maria Papatriantafyllou
The detection of anellovirus or eHHV-6B genomes in the blood virome seems to correlate with the risk or severity of rheumatic diseases and COVID-19.
-
Opportunities and limitations of B cell depletion approaches in SLE Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-01-15 Marit Stockfelt, Y. K. Onno Teng, Edward M. Vital
-
Piezo1 as a therapeutic target for glucocorticoid-induced osteoporosis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-01-10 Holly Webster
A study implicates the Hes1–Piezo1 signalling pathway in osteocytes in the pathogenesis of glucocorticoid-induced osteoporosis and demonstrates the beneficial effects of Yoda1, a Piezo1 agonist.
-
Breaking research silos to achieve equitable precision medicine in rheumatology Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-01-10 Hannah C. Ainsworth, DeAnna Baker Frost, S. Sam Lim, Paula S. Ramos
-
Advances in the calculation of minimal important change estimates for patient-reported outcome measures Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-01-02 Ewa M. Roos
In 2024, studies using more advanced methods to calculate the minimal important change have described how different methods and timings of estimating minimal important changes can affect the estimates.
-
Precision weight management in people with knee osteoarthritis and overweight or obesity Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-12-23 Shiwen Yuan, David J. Hunter
-
Abatacept for myositis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-12-20 Sarah Onuora
In a phase III clinical trial of abatacept for idiopathic inflammatory myopathy, the primary endpoint was not met but the results suggest abatacept could have benefits in some subtypes of the disease.
-
Synovial dendritic cell subsets in RA Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-12-20 Maria Papatriantafyllou
Synovial dendritic cell profiles and localization patterns provide insights about the roles of dendritic cell subsets in the initiation, remission and relapse of rheumatoid arthritis.
-
Blocking CDK7 attenuates inflammatory arthritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-12-20 Sarah Onuora
In a new study, inhibition of CDK7 disrupted the RNA polymerase II transcription cycle, leading to anti-inflammatory effects and metabolic reprogramming in macrophages and attenuation of arthritis in mouse models.
-
European expert recommendations for managing systemic sclerosis and its complications Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-12-20 Robyn T. Domsic
The updated 2023 EULAR recommendations for treatment of systemic sclerosis bring notable changes to recommendations for skin, peripheral vascular disease, interstitial lung disease and pulmonary arterial hypertension therapies, based on newer evidence. These updates provide the first glimmer of personalized patient management.
-
Molecular profiling for advancing precision rheumatology Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-12-20 Coziana Ciurtin, Elizabeth C. Jury
-
Insights into IVDD pathogenesis in 2024 Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-12-20 Daisuke Sakai
Emerging research in intervertebral disc degeneration in 2024 highlights microbial, immune and inflammatory mechanisms that drive chronic low back pain. These insights pave the way for potential transformative therapies that address the root causes of intervertebral disc degeneration and could improve patient outcomes.
-
Antigen-specific immunotherapies for autoimmune disease Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-12-16 Jane H. Buckner
-
Inebilizumab shows promise for IgG4-RD Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-12-11 Sarah Onuora
In a phase III trial, the CD19-targeting antibody inebilizumab was effective for the treatment of IgG4-related disease over 52 weeks.
-
Appraising the evolving landscape of protease inhibition in osteoarthritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-12-11 Muhammad Farooq Rai
The role of proteases in cartilage degradation and the development of osteoarthritis is undeniable. Despite over two decades of research on protease inhibitors, however, the transition from preclinical promise to clinical success remains elusive, underscoring the urgent need to critically appraise the challenges and limitations inherent in preclinical studies.
-
Publisher Correction: Lupus nephritis-related chronic kidney disease Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-12-09 Julia Lichtnekert, Hans-Joachim Anders
Correction to: Nature Reviews Rheumatology https://doi.org/10.1038/s41584-024-01158-w, published online 24 September 2024.
-
The ‘Treg paradox’ in inflammatory arthritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-12-09 Julia T. Schnell, Raquel Laza Briviesca, Taehyeung Kim, Louis-Marie Charbonnier, Lauren A. Henderson, Femke van Wijk, Peter A. Nigrovic
-
A lung–joint axis in smokers with RA? Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-12-04 Maria Papatriantafyllou
Shared T cell clones identified in the lungs and joints of smokers with early RA.
-
Impaired adipocyte-mediated regulation of fibroblasts in inflammatory arthritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-12-03 Holly Webster
A study reports that adipocytes can regulate the metabolism of fibroblasts in the healthy synovium via cortisol, but in inflammatory arthritis adiposity is lost and fibroblasts become pathogenic.
-
Wnt-induced IGF1 drives OA Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-12-03 Sarah Onuora
New research suggests that insulin-like growth factor 1 is an important contributor to Wnt-induced joint damage, and that its suppression could represent a promising therapeutic strategy for osteoarthritis.
-
A subset of ITGA5+ synovial fibroblasts alter the inflammatory niche in RA Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-12-03 Holly Webster
The release of TGFβ by a subset of ITGA5+ synovial fibroblasts can promote the differentiation of pathogenic PD-1hiCXCL13+ T cells in RA, altering the inflammatory niche.
-
DADA2 prevalence in China Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-12-02 Maria Papatriantafyllou
Analysis of exome sequencing data indicates that the prevalence of DADA2 is higher in China compared with other regions.
-
Revisiting the heterogeneity of interferon-related autoimmune diseases Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-12-02 Guillermo Barturen, Marta E. Alarcón-Riquelme
The identification of shared molecular mechanisms across systemic inflammatory autoimmune diseases with overlapping clinical manifestations has prompted research into the underlying genetics that could be driving these manifestations; elucidating these genes could aid in the diagnosis, treatment and outcome prediction of these complex diseases.
-
HLA-B27 and spondyloarthritis: at the crossroads of innate and adaptive immunity Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-12-02 Fatemeh Navid, Liye Chen, Paul Bowness, Robert A. Colbert
-
Emerging concepts and treatments in autoinflammatory interferonopathies and monogenic systemic lupus erythematosus Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-12-02 Raphaela Goldbach-Mansky, Sara Alehashemi, Adriana A. de Jesus
-
An update on autoantibodies in the idiopathic inflammatory myopathies Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-11-28 Nur Azizah Allameen, Ana Isabel Ramos-Lisbona, Lucy R. Wedderburn, Ingrid E. Lundberg, David A. Isenberg
-
The quest for targetable pain mechanisms in 2024 Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-11-25 Neil Basu
Studies published in 2024 suggest that although the repurposing of established rheumatology drugs seems to deliver incremental benefits for pain management, greater benefits could be gained in the future by targeting newly discovered pain mechanisms.
-
EULAR and PReS bridge the age gap in Still’s disease Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-11-25 Qiongyi Hu, Chengde Yang
-
The emergence of SLE-causing UNC93B1 variants in 2024 Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-11-18 George C. Tsokos
During the past year, four studies have reported ten mutations in UNC93B1, which encodes the Toll-like receptor (TLR) chaperone protein UNC93B1. All variants increased TLR7 and TLR8 signalling and caused systemic lupus erythematosus in young individuals, and highlight the therapeutic potential of targeting TLR7 and TLR8 in this disease.
-
Publisher Correction: Recent advances in the diagnosis and management of neuropsychiatric lupus Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-11-13 Alexandra C. Legge, John G. Hanly
Correction to: Nature Reviews Rheumatology https://doi.org/10.1038/s41584-024-01163-z, published online 2 October 2024.
-
The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-11-07 Thomas Dörner, Peter E. Lipsky
-
The management of adult and paediatric uveitis for rheumatologists Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-11-06 Sarah L. N. Clarke, Panagiotis Maghsoudlou, Catherine M. Guly, Andrew D. Dick, Athimalaipet V. Ramanan
-
Dupuytren contracture treatments compared Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-11-05 Sarah Onuora
In an open-label clinical trial, collagenase injection was not noninferior to limited fasciectomy for the treatment of Dupuytren contracture.
-
Novel autoantigen in idiopathic lung disease Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-11-04 Maria Papatriantafyllou
The presence of anti-IFI16 autoantibodies in patients with idiopathic interstitial pneumonia is linked to poor prognosis and could inform treatment.
-
Risk of uveitis in SpA is changing Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-10-31 Sarah Onuora
Findings from an observational study suggest that the frequency of uveitis in patients with spondyloarthritis has declined since the introduction of biologic DMARDs.
-
Rheumatology in the digital health era: status quo and quo vadis? Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-10-31 Johannes Knitza, Latika Gupta, Thomas Hügle
-
Rheumatic diseases and metabolism: where centre and periphery meet Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-10-30 Miguel López, Oreste Gualillo
-
Mito+ RBCs prompt IFN and IL-1β release by SLE monocytes Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-10-23 Holly Webster
In a subset of monocytes in systemic lupus erythematosus, internalization of mitochondria-retaining red blood cells leads to type I interferon-mediated IL-1β release.
-
Management strategies in rheumatoid arthritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-10-24 Victoria Konzett, Daniel Aletaha
-
Osmo-sensitive anion channels reduce crystal-induced inflammation Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-10-16 Holly Webster
New research demonstrates a key role for osmo-sensitive LRRC8 anion channels in crystal-induced inflammation.
-
Erosive cargo from synovial fibroblasts Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-10-15 Maria Papatriantafyllou
Synovial fibroblasts from individuals with OA release small extracellular vesicles with potentially pathogenic miRNA cargo.
-
Somatic mutations in autoinflammatory and autoimmune disease Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-10-11 Sofia Torreggiani, Flore S. Castellan, Ivona Aksentijevich, David B. Beck
-
Epstein–Barr virus as a potentiator of autoimmune diseases Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-10-10 William H. Robinson, Shady Younis, Zelda Z. Love, Lawrence Steinman, Tobias V. Lanz
-
JAK inhibitors improve RA pain Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-10-07 Sarah Onuora
Consistent with findings from clinical trials, in a retrospective cohort study, Janus kinase inhibitors improved pain associated with rheumatoid arthritis as well as or better than biologic DMARDs in clinical practice.
-
Downregulation of invariant chain causes autoreactive T cell expansion Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-10-04 Maria Papatriantafyllou
Neoself-antigens presented by MHC-II molecules in the absence of invariant chain drive clonal expansion of autoreactive T cells in SLE.
-
BiTE therapy for rheumatic diseases Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-10-04 Sarah Onuora
The bispecific T cell engager antibody teclistamab has now been used to successfully treat five patients with treatment-resistant autoimmune rheumatic diseases.
-
Combination therapy for Behçet uveitis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-10-04 Holly Webster
A study has compared the safety and efficacy of three different immunomodulatory drugs combined with glucocorticoids for the treatment of Behçet uveitis.
-
Recent advances in the diagnosis and management of neuropsychiatric lupus Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-10-02 Alexandra C. Legge, John G. Hanly
-
Defining axial involvement in juvenile SpA Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-09-26 Denis Poddubnyy
New classification criteria for axial disease in juvenile spondyloarthritis aim to enhance the identification and study of this condition in affected youth, offering a tool for future non-interventional studies and interventional trials. Better understanding of the efficacy of various interventions in the axial domain could help tailor treatment strategies.
-
The PU.1– IL-9 axis in TH9 cells promotes RA Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-09-25 Holly Webster
Findings show a role for the PU.1–IL-9 axis in TH9 cells in the pathogenesis of RA.
-
Lupus nephritis-related chronic kidney disease Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-09-24 Julia Lichtnekert, Hans-Joachim Anders
-
Publisher Correction: Integrin signalling in joint development, homeostasis and osteoarthritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-09-20 Michael Z. Miao, Janice S. Lee, Kenneth M. Yamada, Richard F. Loeser
Correction to: Nature Reviews Rheumatology https://doi.org/10.1038/s41584-024-01130-8, published online 16 July 2024.
-
Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-09-09 V. Michael Holers, Kristen M. Demoruelle, Jane H. Buckner, Eddie A. James, Gary S. Firestein, William H. Robinson, Allen C. Steere, Fan Zhang, Jill M. Norris, Kristine A. Kuhn, Kevin D. Deane
-
Interferon disrupts immune and tissue homeostasis in SLE via CXCL13 Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-09-09 Mehrdad Pazhouhandeh, Di Yu
-
JAK inhibitor selectivity: new opportunities, better drugs? Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-09-09 Anniina Virtanen, Francesca Romana Spinelli, Jean Baptiste Telliez, John J. O’Shea, Olli Silvennoinen, Massimo Gadina